<DOC>
	<DOCNO>NCT00803920</DOCNO>
	<brief_summary>The purpose substudy obtain CGM data individual take exenatide . The CGM measurement gather start treatment exenatide IR and/or exenatide LAR help determine characteristic glucose control treatment .</brief_summary>
	<brief_title>Continuous Glucose Monitoring ( CGM ) Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide Once-Weekly Exenatide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>participant Amylin Protocol 2993LAR105 least 16 year age type 2 diabetes treat stable regiment metformin , SU , TZD , combination metformin/SU , combination metformin/TZD , combination SU/TZD A1c 7.1 11 fast glucose less 280 screen BMI 25 45 stable body weight 6 month prior screen pregnant willing practice birth control physical exam &amp; ECG clinically significant lab value judge clinically significant able understand &amp; sign consent form clinically significant medical condition judge investigator drug alcohol abuse previous use exenatide GLP1 analog use investigational drug past 30 day prior screen currently use : alphaglucosidase inhibitor , insulin , drug affect GI motility , use systemic corticosteroid , use medication addictive potential , prescription OTC weightloss medication donate blood within 60 day screen , plan donate study major surgery blood transfusion within 2 month screen surgical procedure may impact gastric empty allergy hypersensitivity component study treatment immediate family member personnel affiliate study investigative site employ Amylin , Lilly Alkermes</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>exenatide twice daily weekly</keyword>
	<keyword>continuous glucose monitoring</keyword>
</DOC>